Plasma Levels of GDF-9 and GDF-15 in Patients With Polycystic Ovary Syndrome.
This trial is active, not recruiting.
|Condition||polycystic ovary syndrome|
|Sponsor||Ankara Education and Research Hospital|
|Trial identifier||NCT01644305, 3849|
The purpose of this study is to determine the plasma levels of GDF-9 and GDF-15, and their association with bone and cardiovascular parameters in patients with Polycystic Ovary Syndrome.
|Observational model||case control|
The association of GDF 9 AND GDF 15 with bone and cardiovascular parameters in women with polycystic ovary syndrome
Female participants from 25 years up to 35 years old.
Inclusion Criteria: - Female patients at ages 25-35 diagnosed with polycystic ovarian syndrome and idiopathic hirsutism Exclusion Criteria: - acute infectious disease, a thyroid, pituitary, nutritional, inflammatory, hepatic, renal, or neoplastic disorder; history of cardiovascular disease or pulmonary embolism; a family history of coronary artery disease; smoking history; hypertension; diabetes mellitus; use of oral contraceptives, anti-androgens and drugs known to interfere with cytokine release, such as corticosteroids, immunosuppressors, or nonsteroidal antiinflammatory drugs. any medication known to affect hormonal or metabolic parameters.
Call for more information